Isoniazid-Rifampin Fulminant Hepatitis: A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction

Gastroenterology

Volumn 72, Issue 2, 1977, Pages 284-289

  Pessayre, Dominique ^a,b   Bentata, Michelle ^a,b   Degott, Claude ^a,b   Nouel, Olivier ^a,b   Miguet, Jean Philippe ^a,b   Rueff, Bernard ^a,b   Benhamou, Jean Pierre ^a,b  

^a BEAUJON HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; ETHAMBUTOL; ISONIAZID; MUSCLE RELAXANT AGENT; RIFAMPICIN; SEDATIVE AGENT; STREPTOMYCIN; TRANQUILIZER;

ADVERSE DRUG REACTION; ANESTHESIA; CLINICAL STUDY; COMA; DRUG INTERACTION; DRUG THERAPY; DRUG TOXICITY; ENZYME INDUCTION; HEPATITIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; THERAPY;

ADOLESCENT; ADULT; AGED; ENZYME INDUCTION; FEMALE; HEPATITIS, TOXIC; HUMANS; ISONIAZID; LIVER; MALE; MICROSOMES, LIVER; RIFAMPIN;

EID: 0017350303     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(77)80088-7     Document Type: Article

References (44)

1. Les icteres au cours du traitement par la rifampicine (12 observations)
2. Ictere d'evolution fatale au cours d'un traitement par la rifampicine
3. Les icteres mortels des traitements antituberculeux comportant de la rifampicine
4. Discussion. In Blanchon P, Paillas J, Blanchon B, et al: Les icteres mortels des traitements antituberculeux comportant de la rifampicine
5. Fatal rifampicinisoniazid hepatitis in patients with previously normal liver: clinical and pathological report of two cases
6. A nearly fatal hepatotoxic reaction to rifampin after halothane anesthesia
7. Hepatotoxicity of rifampicin and isoniazid in children
8. Hepatic necrosis associated with halothane anesthesia
9. Antimitochondrial antibodies in jaundice following drug administration
10. Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications
11. Hepatic reactions to drugs
12. Hepatitis after exposure to halothane
13. Halothane hepatitis
14. Donnees nouvelles sur les hepatites observees au cours des traitements antituberculeux incluant la rifampicine
15. Rifampicin hepatitis. A clinical and histological study
16. Fatal hepatic necrosis associated with aminosalicylic acid: review of literature and report of a case
17. Effect of rifampicin on liver function in man
18. Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications
19. Foie et rifampicine
20. Icteres et rifampicine. Etude critique
21. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid
22. Disturbed hepatic function during isoniazid chemoprophylaxis
23. Isoniazid-associated hepatitis
24. Isoniazid-associated hepatitis in 114 patients
25. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy
26. Metabolic activation of drugs to toxic substances
27. Induction and inhibition of hepatic drug metabolizing enzymes by rifampin
28. Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes
29. Half-life of rifampicin after repeated administration of different doses in humans
30. Interaction of sodium warfarin and rifampin
31. Changes in cortisol metabolism following rifampicin therapy
32. Rifampicin and oral contraception
33. 14C in the mouse
34. Difference in the biotransformation of halothane in man
35. Nonspecific stimulation of drug-metabolizing enzymes by inhalation anesthetic agents
36. Further studies on the inhibition and stimulation of microsomal drug-metabolizing enzymes of rat liver by various compounds
37. Drugs as activators of drug enzymes
38. Increase of pentobarbitone metabolism induced in rats pretreated with some centrally acting compounds
39. Studies on the metabolism of meprobamate
40. Effects of various barbiturates on hepatic microsomal enzymes
41. Mechanism of induction of hepatic microsomal drug metabolizing enzymes by a series of barbiturates
42. Pharmacological implications of microsomal enzyme induction
43. Pour une posologie adaptee de l'isoniazide